Evidence map›Paper›PMID 41064806›Full record

ReviewNAR cancer2025

DNA repair helicases: from mechanistic understanding to therapeutic implications.

Vijay Menon, Susan E Gueble

Abstract readReview
In one paragraph

Review in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vijay MenonDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, United States.ORCID 0000-0001-8009-5035
Susan E GuebleDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, United States.ORCID 0000-0002-8043-1147

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9M
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient CancerDP5OD036128 · OD · YALE UNIVERSITY · PI Susan E Gueble · 2023 to 2026
$2.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA121974NIH HHS DP5 OD036128
6 · The paper itself

Abstract

The maintenance of genomic integrity is paramount for normal cell physiology and survival as well as avoidance of carcinogenesis. Cellular DNA is periodically subjected to a myriad of exogenous and endogenous threats and requires constant monitoring to limit genomic instability. To this end, cells possess an intricate DNA damage response and repair (DDR) module comprised of different classes of protein players. The DNA helicases, ATP-dependent enzymes that unwind the DNA double helix, are one such important class of proteins, which act as a linchpin between the recognition and resolution of DNA damage via facilitating various DNA repair processes. Dysfunction or absence of DDR helicase function is implicated in several human disorders including Bloom syndrome, Werner syndrome, Rothmund-Thomson syndrome, and Fanconi anemia. Somatic helicase mutations or dysregulation of helicase function can also contribute to cancer development, progression, and chemotherapy sensitivity, making helicases a promising target class for chemotherapeutic drug intervention. In addition, recent discoveries have identified some DDR helicases in novel synthetic lethal interactions. In this critical review, we will focus on human DNA helicases that are directly or indirectly involved in DDR with special emphasis on their mechanistic actions and clinical implications.

Indexed as

DNA HelicasesDNA RepairNeoplasmsAnimalsDNA DamageHumansMutationDNA Helicases

Identifiers

PMID41064806
PMCPMC12501782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.